Similarly, the very limited data in this study suggest a possible trend towards a reduction in lower extremity amputation rates and a reduction in infection relapse and reinfection rates in pravibismane, compared to placebo treated DFIs.
← all excerpts
Topical pravibismane as adjunctive therapy for moderate or severe diabetic foot infections: A phase 1b randomized, multicenter, double-blind, placebo-controlled trial.
1
—
—